Phase II clinical study of nab-PTX/CBDCA (administer 3-weeks on / 1-week off) for patients with clinical stage IIIB/IV or recurrent NSCLC
Phase 2
- Conditions
- lung cancer
- Registration Number
- JPRN-UMIN000016255
- Lead Sponsor
- Shiga University of Medical Science
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 5
Inclusion Criteria
Not provided
Exclusion Criteria
1.With severe myelosuppression. 2.With the history of hypersensitivity for nab-paclitaxel or CBDCA. 3.With active double cancer. 4.With active infectious disease:temperature=>38 5.With clinically important complications. 6.Interstitial pneumonia or pulmonary fibrosis on chest X-rays. 7.Pregnant females, possibly pregnant females, females wishing to become pregnant and nursing mothers. Males that are currently attempting to produce a pregnancy. 8.Accepted continuous use of steroid. 9.Physician concludes that the patient's participation in this trial is inappropriate.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method response rate
- Secondary Outcome Measures
Name Time Method progression free survival/overall survival/disease control rate/adverse events/completion rate of treatment